Containing Emulsions, Dispersions, Or Solutions Patents (Class 424/455)
-
Publication number: 20100203121Abstract: A process for preparing nanocapsules having a core-shell structure, comprising: (a) preparing an oil-in-water emulsion by emulsification of an oily phase that comprises a core material, in an aqueous phase, under high shear forces, wherein one or both of the oily phase, and the aqueous phase comprises a sol-gel precursor; (b) subjecting the emulsion obtained in (a) to a high pressure homogenization to obtain a nano-emulsion; and (c) applying conditions for hydrolyzing and polycondensing the sol-gel precursor to obtain nanocapsules having a metal oxide shell encapsulating the core material, said nanocapsules have a particle size distribution of: d10=10-80 nm, d50=30-200 nm, and d90=70-500 nm, in diameter. The invention also relate to nanocapsules having the above particle size distribution and to composition comprising the nanocapsules.Type: ApplicationFiled: December 12, 2007Publication date: August 12, 2010Applicant: SOL-GEL TECHNOLOGIES, LTD.Inventors: Ofer Toledano, Hanan Sertchook, Raed Abu-Reziq, Haim Bar-Simantov, Leora Shapiro
-
Patent number: 7771737Abstract: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.Type: GrantFiled: January 9, 2004Date of Patent: August 10, 2010Assignee: Ecolab Inc.Inventors: Victor Fuk-Pong Man, Joshua Paul Magnuson, Steven Eugene Lentsch
-
Publication number: 20100196467Abstract: The present invention especially relates to the use of a combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and (2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein (i) the amount of amlodipine or a pharmaceutically acceptable salt thereof corresponds to 6 about mg to 40 about mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 about mg to 160 about mg ofType: ApplicationFiled: April 16, 2010Publication date: August 5, 2010Inventors: William Lionel Daley, Randy Lee Webb, Ann Reese Comfort, Santo Joseph Fleres, Alan Edward Royce, William Shifeng Wei
-
Publication number: 20100196429Abstract: The present invention provides: an oil-in-water emulsion composition, into which an oil-soluble drug is stably incorporated and which is excellent in feeling during use; and a method for producing the aforementioned composition, which does not require complicated operations. An oil-in-water emulsion composition comprising; (A) a polyoxyethylene phytosterol, (B) a glycerin fatty acid diester, (C) a polyoxyethylene-polyoxypropylene random copolymer dialkyl ether, (D) an oil-soluble drug, (E) oil, and (F) water; wherein a layered gel structure composed of the components (A) and (B) is present in an emulsion particle in the emulsion composition.Type: ApplicationFiled: July 22, 2008Publication date: August 5, 2010Applicant: SHISEIDO COMPANY LTD.Inventors: Takashi Oka, Reiji Miyahara, Takashi Teshigawara
-
Patent number: 7763278Abstract: The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.Type: GrantFiled: June 10, 2003Date of Patent: July 27, 2010Assignee: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, Laura Kline, Gary G. Liversidge, Niels P. Ryde
-
Patent number: 7758891Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.Type: GrantFiled: December 12, 2008Date of Patent: July 20, 2010Assignee: Abraxis Bioscience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20100178335Abstract: The present invention relates to new formulations comprising acetylsalicylic acid or its derivatives an oil phase and a cyclodextria in soft capsules, characterized by a high stability.Type: ApplicationFiled: August 30, 2007Publication date: July 15, 2010Inventors: Angel Mateo Echanagorria, Maurizio Marchiorri, Giorgio Zoppetti
-
Patent number: 7744858Abstract: The present invention relates to a composition for topical application, comprising at least one electrolyte and at least one amphiphilic polymer including at least one ethylenically unsaturated monomer containing a sulphonic group, in free form or partially or totally neutralized form and comprising at least one hydrophobic portion. The invention also relates to the uses of the said composition, especially in cosmetics, to treat and care for human skin, the scalp, mucous membranes, the nails and keratin fibres.Type: GrantFiled: January 8, 2002Date of Patent: June 29, 2010Assignee: L'OrealInventors: Raluca Lorant, Paula Lennon
-
Publication number: 20100143462Abstract: The present invention relates to pharmaceutical compositions in the form of microcmulsions comprising carbamazcpinc and their enhanced permeability and extended release properties. The microcmulsion composition may be an oil based formulation or a oil/aqueous phase mixed formulation.Type: ApplicationFiled: December 6, 2005Publication date: June 10, 2010Applicant: NUTRALEASE LTD.Inventors: Nissim Garti, Abraham Aserin, Anna Kogan
-
Publication number: 20100136105Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.Type: ApplicationFiled: November 24, 2009Publication date: June 3, 2010Applicant: LIPOCINE, INC.Inventors: FENG-JING CHEN, MAHESH V. PATEL, DAVID T. FIKSTAD, HUIPING ZHANG, CHANDRASHEKAR GILIYAR
-
Patent number: 7713523Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 and an amino acid solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 and the amino acid, such as carnitine, i.e., carnitine tartrate, in formulations, such as soft gel capsules.Type: GrantFiled: September 24, 2007Date of Patent: May 11, 2010Assignee: Soft Gel Technologies, Inc.Inventors: Michael Fantuzzi, Ronald G. Udell
-
Publication number: 20100086587Abstract: Hard shell capsules filled with a normally hygroscopic formulation and a method for producing the same is described. The hard shell capsules are filled with a normally hygroscopic formulation including, for example, an excipient, and optionally an active compound. The water content of the formulation and the hard shell capsule are in equilibration, and the formulation is hydrated by an amount selected to control equilibrium between said formulation and the hard shell capsule, and to provide a structurally stable hard shell capsule. The active compound may be a protein or peptide.Type: ApplicationFiled: December 17, 2007Publication date: April 8, 2010Inventors: Victor Morrison Young, Stephen Brown
-
Patent number: 7691411Abstract: The present invention provides pharmaceutical formulation for thyroid hormones which allow safe and stable administration by mouth within the ambit of the narrow therapeutic index prescribed in the case of thyroid dysfunctions, as well as procedures for obtaining them.Type: GrantFiled: December 23, 2003Date of Patent: April 6, 2010Assignee: Altergon S.A.Inventors: Alessandro Di Martino, Angel Mateo, Alberto Garavani, Maurizio Marchiorri
-
Publication number: 20100062057Abstract: Novel capsules comprising a marine oil in an outer shell comprising alginate are disclosed. Also disclosed are methods of preparing the novel capsules and uses of thereof.Type: ApplicationFiled: September 10, 2008Publication date: March 11, 2010Inventors: Gunnar BERGE, Svein Olaf Hustvedt, Thomas Andersen
-
Patent number: 7670618Abstract: Discloses is a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution containing: (a) a pharmaceutically effective amount of a cyclosporin, in particular Cyclosporin A, (b) a carrier medium which is a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures of such fatty acids, wherein the monoester makes up less than 60 mol % of the mixture, and (c) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10.Type: GrantFiled: August 4, 2003Date of Patent: March 2, 2010Inventor: Satishchandra P. Patel
-
Patent number: 7662406Abstract: A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like.Type: GrantFiled: August 18, 2009Date of Patent: February 16, 2010Assignee: Viva Pharmaceutical Inc.Inventors: Xueju Xie, Yu-Lung Ko, Chien-Kuang Ko, Jason Jiang-Chung Ko
-
Patent number: 7658943Abstract: The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.Type: GrantFiled: March 18, 2005Date of Patent: February 9, 2010Assignee: R.P. Scherer Technologies, LLCInventors: Joel Bougaret, Elie Leverd, Marie-Madeleine Bohn, Norbert Heintz
-
Publication number: 20090324711Abstract: An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML.Type: ApplicationFiled: July 5, 2007Publication date: December 31, 2009Applicant: Ares Trading S.A.Inventors: Santa Fabiano, Mario Maio
-
Publication number: 20090304788Abstract: A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution. Additional embodiments are disclosed.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Kyekyoon Kim, Hyungsoo Choi
-
Patent number: 7622132Abstract: The present invention relates to encapsulated cosmetic compositions that are topically applied. The compositions contain at least one frangible capsule that has a seamless shell of a thermo-softening material. The shell is solid at about room temperature and melts upon application to the skin. The shell holds a core cosmetic that is added to a clear gel base. Thus, the color of the capsule is visible and multiple colored capsules can be added to the base for a custom colored composition.Type: GrantFiled: June 21, 2006Date of Patent: November 24, 2009Assignee: ELC Management, LLCInventors: Wilson An-Tuen Lee, Leigh Andersen Silveira
-
Publication number: 20090269398Abstract: The present invention relates to compositions of natural extracts in oil medium, prepared in non-free-flowing formulations, and encapsuled in hard gelatin capsules, without post-fill sealing. These compositions comprise a therapeutically effective amount of at least one natural extract in oil medium, the composition suitable for treating a medical condition, and at least one oil-absorbent ingredient in powder form. More specifically, the natural extract in the composition can be an extract of Wrightia tinctoria, which is suitable for treating medical conditions, such as, but not limited to, relief from pain, psoriasis, eczema, spondolytis, acne and wound care. The invention also provides a method for encapsulating the natural extracts in oil medium compositions, compounded in a non-free-flowing formulation, in hard gelatin capsules without the need for post-fill sealing.Type: ApplicationFiled: April 26, 2008Publication date: October 29, 2009Inventors: Vilambi NRK Reddy, Anil Torgalkar
-
Publication number: 20090252788Abstract: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.Type: ApplicationFiled: February 22, 2008Publication date: October 8, 2009Applicant: Salix Pharmaceuticals, Inc.Inventors: Joseph Lockhart, Brock Swanson, Lorin Johnson
-
Publication number: 20090246275Abstract: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.Type: ApplicationFiled: March 10, 2009Publication date: October 1, 2009Inventors: John O'Gara, Sonali Puri
-
Publication number: 20090238867Abstract: Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.Type: ApplicationFiled: December 9, 2008Publication date: September 24, 2009Inventors: Scott Jenkins, Gary Liversidge, Deborah Neville
-
Publication number: 20090238866Abstract: The invention provides an orally administrable chewable capsule comprising a capsule shell enclosing an oil-in-water emulsion in which the aqueous phase is gelled, or an oil droplet-containing dried residue of such an emulsion.Type: ApplicationFiled: January 25, 2007Publication date: September 24, 2009Applicant: Probio Nutraceuticals ASInventors: Ingvild Haug, Kurt Ingar Draget
-
Publication number: 20090232885Abstract: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer; the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt.% of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—paddles@ 50 RPM and a two-stage dissolution medium at 37° C., (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8).Type: ApplicationFiled: September 12, 2008Publication date: September 17, 2009Inventors: Gopi Venkatesh, Jin-Wang Lai, Nehal H. Vyas, Vivek Purohit
-
Patent number: 7569232Abstract: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.Type: GrantFiled: January 4, 2005Date of Patent: August 4, 2009Assignee: Ecolab Inc.Inventors: Victor Fuk-Pong Man, Joshua Paul Magnuson, Steven Eugene Lentsch
-
Patent number: 7566442Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for ?v?3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.Type: GrantFiled: January 9, 2008Date of Patent: July 28, 2009Assignees: Barnes-Jewish Hospital, Bristol Myers Squibb Medical Imaging, Inc.Inventors: Gregory M. Lanza, Samuel A. Wickline, Tom Harris
-
Publication number: 20090181079Abstract: The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3?-gallate and theaflavin 3,3?-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent various diseases. The present invention also discloses methods of making theaflavin, theaflavin-3-gallate, theaflavin-3?-gallate and theaflavin 3,3?-digallate, each as a separate compound, pharmaceutical compositions of the above compounds, diet supplement compositions of the above compounds and methods for using the above compounds to treat or prevent various diseases.Type: ApplicationFiled: September 22, 2008Publication date: July 16, 2009Inventors: Jian Zhao, Rui Zhou, Hu Chen
-
Patent number: 7553844Abstract: The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency Virus (HIV) protease enzyme. This drug combination is capable of inhibiting the replication of both HIV and Plasmodium sp. It also relates to the direct antimalarial effects of the HIV PIs.Type: GrantFiled: February 20, 2004Date of Patent: June 30, 2009Assignee: Jarrow Formulas, Inc.Inventor: Andrea Savarino
-
Publication number: 20090155355Abstract: The invention relates to a capsule containing a heterogeneous mixture of active agents in the form of particles suspended in a liquid matrix and optionally active ingredients in the liquid matrix; the liquid matrix occupying less than the total internal volume of the capsule. The present invention further describes a capsule to allow the controlled-release of one or more active agents for specific desired benefits.Type: ApplicationFiled: December 12, 2007Publication date: June 18, 2009Applicant: Multi Formulations Ltd.Inventors: Marvin A. Heuer, Jason Peters
-
Patent number: 7541347Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: April 2, 2007Date of Patent: June 2, 2009Assignee: Medicis Pharmaceutical CoroprationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20090130199Abstract: The invention relates to a respiratory preparation providing cough relief in a human comprising: a film forming agent; a thickening agent; and the respiratory preparation provides on demand relief. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a film forming agent; a thickening agent; and wherein said respiratory preparation provides on demand cough relief as needed.Type: ApplicationFiled: November 20, 2008Publication date: May 21, 2009Applicant: The Procter & Gamble CompanyInventors: Stephen Andras Kovacs, Jeffrey Alan Sargent, Helen Rochelle Kemp, Kristin Rhedrick Williams, Mary Lynn Jump
-
Publication number: 20090130198Abstract: The invention pertains to a self-emulsifying pharmaceutical composition containing a lipophilic drug, a surfactant, and a hydrophilic carrier. The invention also provides a method for making the pharmaceutical composition for increasing the bioavailability of a drug by self-emulsification.Type: ApplicationFiled: November 21, 2007Publication date: May 21, 2009Applicant: INNOPHARMAX INC.Inventors: Wei-Hua Hao, Jong-Jing Wang, Chang-Shan Hsu
-
Patent number: 7498309Abstract: Disclosed are pharmaceutical compositions suitable for oral administration of bioactive peptides. Particularly, the pharmaceutical compositions comprise peptides formulated as suspensions stabilized with a dispersing agent. The compositions may be encapsulated in capsules for oral administration. The compositions show improved dissolution characteristics, which are believed to make them suitable for use in the treatment of gastrointestinal disorders.Type: GrantFiled: November 29, 2004Date of Patent: March 3, 2009Assignee: Sangstat Medical CorporationInventor: Ralph E. Levy
-
Publication number: 20090053305Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Type: ApplicationFiled: July 31, 2008Publication date: February 26, 2009Applicant: Abbott LaboratoriesInventors: Laman Alani, Soumojeet Ghosh
-
Publication number: 20090047341Abstract: The present invention relates to a process for the preparation of a suspension of capsules of core/shell type comprising the steps of mixing, at ambient temperature, an oily phase and polymers, at least one of which is an oligomer having a weight-average molecular weight of less than 10 000 and a hydroxyl number (NOH) of greater than or equal to 10 mg KOH/g, of homogenizing the oily phase and the polymers by heating, of dispersing the homogeneous mixture thus obtained in an aqueous phase, in order to obtain a direct preemulsion, the oily phase of which comprises the polymers, of subjecting the preemulsion thus obtained to shear forces appropriate for the reduction in the diameter of the particles of the dispersed mixture, of cooling the emulsion thus obtained to a temperature suitable for the coacervation of the said polymers and for the coating of drops of the said oily phase by the coacervates, and of cooling the suspension to a temperature suitable for the formation of the capsules by the precipitation andType: ApplicationFiled: July 1, 2008Publication date: February 19, 2009Applicant: L'OREALInventors: Jean-Thierry SIMMONET, Bruno BIATRY, Fanny PRIGENT
-
Publication number: 20090011009Abstract: The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.Type: ApplicationFiled: July 23, 2008Publication date: January 8, 2009Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Shimon Benita, Alona Rom, Taher Nasser
-
Publication number: 20090004261Abstract: this invention discloses and claims a pharmaceutical composition in liquid or semi-liquid form, which is self-emulsifying or self-microemulsifying in aqueous medium, for the oral administration of a pyrazole-3-carboxamide derivative, in which said derivative is dissolved in an amphiphilic mixture containing one or more lipid solvents and a nonionic hydrophilic surfactant.Type: ApplicationFiled: September 9, 2008Publication date: January 1, 2009Applicant: Sanofi-aventisInventors: Thierry BREUL, Jean-Claude Gautier, Olivier Saslawski
-
Publication number: 20080305152Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.Type: ApplicationFiled: February 11, 2005Publication date: December 11, 2008Applicant: CLINUVEL PHARMACEUTICALS LIMITEDInventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
-
Publication number: 20080279928Abstract: The invention concerns a method for producing ultrafine suspensions, characterized in that a substance in the form of a solid product at 20° C. is dissolved in a solvent, in that the solvent is very rapidly substantially drawn from said solution, in that the powder thus obtained, whereof the particles have an average particle-size distribution of the order of 1 to 50 ?m (by laser diffractometry) is dispersed in a dispersing medium, and in that the resulting suspension is treated subsequently, using average to high forces, so as to obtain a suspension whereof the solid matter particles have a average particle-size distribution (by photon correlation spectroscopy) less than 3 ?m, preferably less than 1 ?m (1000 nm), and in particular less than 400 nm, more particularly still, less than 200 nm.Type: ApplicationFiled: March 9, 2006Publication date: November 13, 2008Inventor: Jan Moschwitzer
-
Publication number: 20080260816Abstract: A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media. Also disclosed is a method of producing the composition and a tablet containing it; sachets and capsules filled with the composition; use of the composition and the tablet as a medicine; a method of administering the composition to a patient.Type: ApplicationFiled: September 11, 2006Publication date: October 23, 2008Inventors: Bengt Herslof, Per Tingvall, Anna De Kornfeldt
-
Publication number: 20080260815Abstract: Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit® RSPO, a plasticising excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit® RLPO. The obtained multiparticulates show a release rate profile which is pH-independent.Type: ApplicationFiled: August 31, 2005Publication date: October 23, 2008Inventors: Geoffrey Gerard Hayes, Vincenzo Martinelli, Hassan Mohammad, Harjit Tamber, Malcolm Walden, Steve Whitelock
-
Publication number: 20080241234Abstract: The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.Type: ApplicationFiled: November 20, 2007Publication date: October 2, 2008Applicant: WYETHInventors: Mahesh K. KRISHNAN, Mohamed GHORAB, Rolland W. CARSON, Shamim HASAN, Arwinder NAGI, Patricia Carson
-
Publication number: 20080233185Abstract: The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB.Type: ApplicationFiled: August 2, 2007Publication date: September 25, 2008Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel, Peter Petzelbauer
-
Patent number: 7416869Abstract: Aqueous enzyme delivery systems as well as aqueous cosmetics and personal care products were provided which comprise at least one stabile enzyme and a polyglycerol containing at least 15 carbons. In addition, stabile non-aqueous enzyme delivery systems which are dispersions of at least one enzyme in an non-aqueous viscous liquid as well as a methods for the treatment of human skin in recreational water applications by means of enzymes are provided.Type: GrantFiled: August 19, 2004Date of Patent: August 26, 2008Assignee: Lonza Ltd.Inventors: Jacob Guth, Vickie Lentner
-
Publication number: 20080199516Abstract: A microcapsule comprising a lipid-based core that is encapsulated in an enteric polymer shell providing enhanced bioavailability of a sparingly water-soluble drug as well as modulated release of the drug, wherein the microcapsule is, in one embodiment, prepared by a centrifugal coextrusion process. The lipid-based core comprises lipidic carriers, either liquid or solid (melting point<1000C), that would provide adequate drug solubilization and is compatible with the enteric shell materials.Type: ApplicationFiled: July 24, 2006Publication date: August 21, 2008Inventor: Stephen Mark Mcallister
-
Publication number: 20080175900Abstract: The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.Type: ApplicationFiled: November 20, 2007Publication date: July 24, 2008Applicant: WYETHInventors: Mahesh K. KRISHNAN, Mohamed GHORAB, Rolland W. CARSON, Patricia Carson, Shamim HASAN, Arwinder NAGI
-
Patent number: RE40786Abstract: This invention relates to parenteral and mucosal vaccines against diseases caused by intercellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).Type: GrantFiled: June 2, 2000Date of Patent: June 23, 2009Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Paul R. Burnett, John E. van Hamont, Robert H. Reid, Jean A. Setterstrom, Thomas C. Van Cott, Deborah L. Birx
-
Patent number: RE40812Abstract: A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration. A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof.Type: GrantFiled: February 5, 2004Date of Patent: June 30, 2009Assignee: Unigene Laboratories Inc.Inventor: William Stern